中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2010年
4期
435-437
,共3页
陈晓鹏%童朝刚%徐龙帅%张帆%王永%王东%王冠男
陳曉鵬%童朝剛%徐龍帥%張帆%王永%王東%王冠男
진효붕%동조강%서룡수%장범%왕영%왕동%왕관남
胃癌%淋巴结%伊立替康%亚甲蓝%示踪剂
胃癌%淋巴結%伊立替康%亞甲藍%示蹤劑
위암%림파결%이립체강%아갑람%시종제
Stomach carcinoma%Lymph node%Irinotecan%Methylene blue%Tracer agent
目的 探讨伊立替康与亚甲蓝耦合液在大鼠胃癌淋巴结中的靶向示踪作用及其机制.方法 应用Walker-256细胞株建立大鼠胃癌模型,免疫组织化学检测癌组织中伊立替康底物拓扑异构酶Ⅰ(topo Ⅰ)的表达.分别用5、10、20、40 mg伊力替康粉剂耦合2 ml亚甲蓝注射液,另用中华墨汁、纳米活性炭和亚甲蓝作为对照.70只胃癌大鼠分为7组,瘤周4点浆膜下微针分别注射上述7种染色剂.观察各组淋巴结染色、褪色时间、染色淋巴结数等指标.结果 (1)建立大鼠胃癌模型符合实验要求,癌组织中topo Ⅰ的表达显著增强.(2)中华墨汁、纳米活性炭和亚甲蓝到达胃癌第1站淋巴结平均时间依次为20、4 min和14 s;4组耦合剂分别为19、27、41、61 s.染料运行至第2站淋巴结的平均时间与之相似.(3)中华墨汁、纳米活性炭和亚甲蓝组平均染色淋巴结数量分别为2、7和8枚;各耦合剂组淋巴结检出数量逐渐增加,依次为8、8、9和11枚.(4)淋巴结褪色时间中华墨汁>2.4h,亚甲蓝102 min,其余各组介于两者之间.(5)各组动物未见明显不良反应.结论 通过靶向结合癌组织中的topo Ⅰ,适当剂量的伊立替康与亚甲蓝耦合剂可显著延长大鼠胃癌淋巴结染色和褪色时间,提高淋巴结靶向示踪效率.
目的 探討伊立替康與亞甲藍耦閤液在大鼠胃癌淋巴結中的靶嚮示蹤作用及其機製.方法 應用Walker-256細胞株建立大鼠胃癌模型,免疫組織化學檢測癌組織中伊立替康底物拓撲異構酶Ⅰ(topo Ⅰ)的錶達.分彆用5、10、20、40 mg伊力替康粉劑耦閤2 ml亞甲藍註射液,另用中華墨汁、納米活性炭和亞甲藍作為對照.70隻胃癌大鼠分為7組,瘤週4點漿膜下微針分彆註射上述7種染色劑.觀察各組淋巴結染色、褪色時間、染色淋巴結數等指標.結果 (1)建立大鼠胃癌模型符閤實驗要求,癌組織中topo Ⅰ的錶達顯著增彊.(2)中華墨汁、納米活性炭和亞甲藍到達胃癌第1站淋巴結平均時間依次為20、4 min和14 s;4組耦閤劑分彆為19、27、41、61 s.染料運行至第2站淋巴結的平均時間與之相似.(3)中華墨汁、納米活性炭和亞甲藍組平均染色淋巴結數量分彆為2、7和8枚;各耦閤劑組淋巴結檢齣數量逐漸增加,依次為8、8、9和11枚.(4)淋巴結褪色時間中華墨汁>2.4h,亞甲藍102 min,其餘各組介于兩者之間.(5)各組動物未見明顯不良反應.結論 通過靶嚮結閤癌組織中的topo Ⅰ,適噹劑量的伊立替康與亞甲藍耦閤劑可顯著延長大鼠胃癌淋巴結染色和褪色時間,提高淋巴結靶嚮示蹤效率.
목적 탐토이립체강여아갑람우합액재대서위암림파결중적파향시종작용급기궤제.방법 응용Walker-256세포주건립대서위암모형,면역조직화학검측암조직중이립체강저물탁복이구매Ⅰ(topo Ⅰ)적표체.분별용5、10、20、40 mg이력체강분제우합2 ml아갑람주사액,령용중화묵즙、납미활성탄화아갑람작위대조.70지위암대서분위7조,류주4점장막하미침분별주사상술7충염색제.관찰각조림파결염색、퇴색시간、염색림파결수등지표.결과 (1)건립대서위암모형부합실험요구,암조직중topo Ⅰ적표체현저증강.(2)중화묵즙、납미활성탄화아갑람도체위암제1참림파결평균시간의차위20、4 min화14 s;4조우합제분별위19、27、41、61 s.염료운행지제2참림파결적평균시간여지상사.(3)중화묵즙、납미활성탄화아갑람조평균염색림파결수량분별위2、7화8매;각우합제조림파결검출수량축점증가,의차위8、8、9화11매.(4)림파결퇴색시간중화묵즙>2.4h,아갑람102 min,기여각조개우량자지간.(5)각조동물미견명현불량반응.결론 통과파향결합암조직중적topo Ⅰ,괄당제량적이립체강여아갑람우합제가현저연장대서위암림파결염색화퇴색시간,제고림파결파향시종효솔.
Objective To evaluate the targeted tracing of irinotecan coupled with methylene blue (MB) for lymph nodes of gastric cancer in rats and explore its mechanism. Methods The rat implanted gastric tumor model was established with malignant tumor cell line Walker-256 and identified, and the topo-ismerase Ⅰ (topo Ⅰ) , the substrate of irinotecan, was immunohistologically detected in cancer tissues. Five, 10, 20 and 40 mg ofirinotecan powder was coupled with 2 ml of methylene blue (MB) injection, re-spectively; and Chinese ink (CI) , nanometric activated carbon (NAC) and MB were used as controls. Seventy rats with gastric cancer were randomly divided into 7 groups. The 7 kinds of tracer agents were in-jected into the peritumoral subserosa at 4 points with microacupuncture needle. The dyeing time, discolora-tion time, number of dyeing lymph nodes, and hepatorenal function of each group were observed. Results (1) The established rat model of gastric cancer was consistent with experimental requiremen, and the ex-pression of topo Ⅰ in cancer tissues was significantly enhanced; (2) The time from the injection to the 1st station lymph nodes was 20 min, 4 min and 14 s in CI, NAC and MB groups, respectively; and the time of various kinds of coupling media was 19, 27, 41 and 61 s, respectively. The time of various kinds of tracer agents to the 2nd station lymph nodes was similar with that to the 1st station lymph nodes; (3) The average number of dyeing lymph nodes was 2, 7, 8 in CI, NAC and MB groups, respectively; the number in vari-ous kinds of coupling media groups was 8, 8, 9 and 11 respectively; (4) The average discoloration time was > 24 h in CI group, 102 min in MB group, and 2-24 h in the rest groups, respectively; (5) No obvi-ous side effect was observed in all groups. Conclusion By targetedly inhibiting the activity of Topo Ⅰ in cancer tissues, adequate dosage of irinotecan coupled with MB may significantly prolong the lymph node dyeing and discoloration time of stomach cancer, and improve the efficiency of targeting lymph node tracing.